Quotes 5-day view Delayed Nasdaq
02/22/2021
02/23/2021
02/24/2021
02/25/2021
02/26/2021
Date
214.96(c)
216.44(c)
217.04(c)
212.98(c)
210.89 Last
3 671 871
2 600 916
1 775 785
1 830 557
1 587 872 Volume
+3.84% +0.69% +0.28% -1.87% -0.98% Change
Sales 2021
6 947 M - -
Net income 2021
2 558 M - -
Net cash position 2021
9 146 M - -
P/E ratio 2021
21,6x
Yield 2021
-
Sales 2022
7 674 M - -
Net income 2022
2 994 M - -
Net cash position 2022
13 106 M - -
P/E ratio 2022
19,0x
Yield 2022
-
Capitalization
55 366 M 55 366 M -
EV / Sales 2021
6,65x
EV / Sales 2022
5,51x
Nbr of Employees
3 400
Free-Float
99,8%
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows:
- income from sales of products (99.9%);
- royalties and income from partnership, research, and development agreements (0.1%).
Net sales break down geographically...
Notations Surperformance© of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
All news about VERTEX PHARMACEUTICALS
News in other languages on VERTEX PHARMACEUTICALS
Analyst Recommendations on VERTEX PHARMACEUTICALS
Chart VERTEX PHARMACEUTICALS
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends VERTEX PHARMACEUTICALS
Short Term Mid-Term Long Term Trends Bearish Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
30
Average target price
283,73 $
Last Close Price
212,98 $
Spread / Highest target
62,9%
Spread / Average Target
33,2%
Spread / Lowest Target
17,4%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
